LDL Cholesterol – Medxy AI

Reevaluating Mortality Risks: The Paradox of Low Apolipoprotein B and LDL-Cholesterol Levels in Cardiovascular Health

By MedXY 09/24/2025

This study finds an unexpected association between low levels of apolipoprotein B and LDL-cholesterol with increased all-cause and cardiovascular mortality, highlighting the complex role of lipid markers in mortality risk assessment.

Clinical Updates Wellness & Lifestyle

Evolocumab and Saphenous Vein Graft Patency Post-CABG: Insights from the NEWTON-CABG Trial

By MedXY 09/21/2025

The NEWTON-CABG CardioLink-5 trial found that intensive LDL-C lowering with evolocumab did not improve saphenous vein graft patency 24 months after coronary artery bypass surgery despite significant LDL-C reductions.

Clinical Updates Wellness & Lifestyle

Obicetrapib: A Promising Advance in LDL Cholesterol Lowering for High Cardiovascular Risk Patients

By MedXY 09/07/2025

Obicetrapib significantly reduces LDL cholesterol by nearly 30% in high-risk cardiovascular patients on maximal lipid therapy, with a safety profile comparable to placebo, representing a potential novel agent in managing familial hypercholesterolemia and atherosclerotic cardiovascular disease.

Clinical Updates Wellness & Lifestyle

Berberine and Cinnamon Synergy: A Promising Adjunct Therapy for Improving Glycemic Control and LDL Cholesterol in Type 2 Diabetes

By MedXY 08/24/2025

A 12-week randomized controlled trial demonstrated that supplementation with berberine plus cinnamon significantly lowers fasting blood sugar, HbA1c, and LDL cholesterol in patients with type 2 diabetes, offering potential for improved cardiometabolic risk management.

Clinical Updates Wellness & Lifestyle

Evolocumab for Intensive LDL Cholesterol Reduction in Autoimmune and Inflammatory Disease Patients: Insights from the FOURIER Trial

By MedXY 08/17/2025

Evolocumab significantly lowers LDL cholesterol and substantially reduces cardiovascular events in patients with autoimmune/inflammatory diseases alongside statin therapy, according to the FOURIER trial analysis.